Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses
about
Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillationCost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation--a real patient data analysis in a Hong Kong teaching hospital.Warfarin treatment among Finnish patients with atrial fibrillation: retrospective registry study based on primary healthcare dataDabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugsEconomic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands.Recovery of visual function after administration of dabigatran etexilate.Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settingsNovel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models.Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany.Cost considerations in the management of atrial fibrillation - impact of dronedarone.Costs and clinical consequences of suboptimal atrial fibrillation management.Dabigatran for stroke prevention in nonvalvular atrial fibrillation: answers to challenging "real-world" questions.Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwideCost of atrial fibrillation: invasive vs non-invasive management in 2012Effects of computer-assisted oral anticoagulant therapy.The Influence of Socioeconomic Status on Selection of Anticoagulation for Atrial FibrillationCost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥ 65 Years With Nonvalvular Atrial FibrillationDabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillationCost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin.Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation.Novel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation--a cost-effectiveness analysis.New oral anticoagulants for atrial fibrillation: are they worth the risk?Prediction of warfarin dose: why, when and how?Anticoagulant therapy for patients with ischaemic stroke.Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran.Stop the clots, but at what cost? Pharmacoeconomics of dabigatran etexilate for the prevention of stroke in subjects with atrial fibrillation: a systematic literature review.Does warfarin use impact hospital length of stay? A retrospective study looking at patients treated for atrial fibrillation.The hidden costs of anticoagulation in hospitalized patients with non-valvular atrial fibrillation.Expanding role of pharmacogenomics in the management of cardiovascular disorders.Target specific oral anticoagulants in the management of thromboembolic disease in the elderly.Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal.Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure.Personalizing oral anticoagulant treatment in patients with atrial fibrillation.Cost effectiveness of treatments for stroke prevention in atrial fibrillation: focus on the novel oral anticoagulants.Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation.Genotype-guided coumarin dosing: where are we now and where do we need to go next?
P2860
Q28484289-E5FA7A32-A708-48C3-91E9-80659BBD4098Q30598904-82AAAA97-6003-4196-9330-B0E0E0D0D24AQ30766944-02DB2C6D-3C5A-4A58-B3B5-3DAC4CB9A4FAQ33730353-B202F552-4C36-4D94-92F8-E0F45F0F1E18Q34004770-4AC38F3A-B19B-484F-B992-3F6C034498E3Q34178949-BDBD34B0-8E3D-4189-86CC-BB55DFCD65F0Q34604533-5E34640D-A39D-4FC1-BC2E-544073AC6E6AQ34692850-7ACA4245-D3E4-4DD0-924B-CC5452A5C21DQ35234175-3650180B-571A-4E4F-8DEE-3A1A55FE7706Q35832134-D80BFACB-D21D-45BE-8780-BE4E2B1544EEQ35885128-EE4EB557-F0FE-4E41-A209-C35C9A45F5ECQ35975334-23989B3A-E9F5-41E9-A33A-86F83E443AACQ36232280-8DF189EE-5F84-469A-86F4-AEDFA59A8111Q36382393-375566A6-6612-457B-B6F1-42622B407095Q36411919-215F4C02-89EF-4B82-8C2F-350A8D4345EDQ36620779-3E8BA8CF-21CE-4DB0-B35A-909ABBC82302Q36657598-C123F307-99B1-427C-A8D8-91850603182AQ36841028-185AC14C-1FFC-4F39-9877-703674AB11CBQ36952091-15824DEE-AF3F-4850-8DF5-04BD7BF7C44EQ37052293-4E072C40-2007-464D-A4DF-576264A1D51CQ37108889-8BC7BF2B-C555-47DB-A5F4-3359E8E6CE20Q37307689-51058AC6-AC2A-471E-B0C5-DAEBE9D37E2DQ37595758-E9186C32-EDC0-40F4-8769-AAD3E98482C3Q37641289-5CCF5735-6568-4C5B-9191-AD450D995EF9Q37989489-E7CE9DC9-979B-4656-B1B7-CBA13FF93DF0Q38008152-48B32C87-0788-4DCD-80F1-04F9ED0F665CQ38021821-D5AEFE52-ABA3-4ECB-8590-8342992E285EQ38042441-E0D79769-625A-4FDC-9AD8-4CBF3355DE11Q38061141-549642AF-E806-48CB-92A7-D39DE452B345Q38080912-E4CE6504-E165-49BF-A5D0-399ECC915794Q38083318-35DBDAF2-3962-4AE5-A063-F046A05B6992Q38097972-2AF8BB4D-85F4-4E74-8298-3EF42B62A5AAQ38098452-C73A0551-8933-4BBE-9B14-5E8357381DE9Q38099775-80CED72E-4F13-4181-810E-677E148785B7Q38101892-9FAB7923-43D2-4E72-89E3-B0D14A77CB3CQ38116784-DF95D8E3-16D7-435D-9B80-75FCED00EFF4Q38129965-8FBC6362-2BFD-4E65-93B7-15CE513E8BE8Q38148500-E5F0265A-6A6E-4442-867D-8CF31E7B8F66Q38303442-39790F36-36FB-4F02-A213-E168E1C2FB1BQ38321269-97477F88-663A-4947-995A-0181C533091E
P2860
Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Dabigatran etexilate versus wa ...... fit-harm and economic analyses
@ast
Dabigatran etexilate versus wa ...... fit-harm and economic analyses
@en
type
label
Dabigatran etexilate versus wa ...... fit-harm and economic analyses
@ast
Dabigatran etexilate versus wa ...... fit-harm and economic analyses
@en
prefLabel
Dabigatran etexilate versus wa ...... fit-harm and economic analyses
@ast
Dabigatran etexilate versus wa ...... fit-harm and economic analyses
@en
P2860
P356
P1433
P1476
Dabigatran etexilate versus wa ...... fit-harm and economic analyses
@en
P2093
Joshua Pink
Steven Lane
P2860
P356
10.1136/BMJ.D6333
P407
P577
2011-10-31T00:00:00Z